BIZARRE: Is merck stock outperforming the nasdaq | Mind Blowing Facts

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global research-driven biopharmaceutical company focused on developing medicines, vaccines, and animal-health products. Known as MSD outside the U.S. and Canada, Merck operates through two main businesses: Pharmaceuticals and Animal Health. Valued at a market cap of $297 billion, its pharmaceutical portfolio spans oncology, vaccines, cardiometabolic disease, infectious diseases, and other therapeutic areas.

Companies with a market cap of $200 billion or more are typically referred to as “mega-cap stocks.” It fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry. Merck combines a dominant oncology franchise, a broad vaccine portfolio, an expanding pipeline of newer medicines, and a large animal-health business. Its key investment consideration is balancing the continued strength of Keytruda and newer products against pressure on mature franchises such as Gardasil and the eventual impact of Keytruda's patent expiry.